Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P220014/S013

CraniSeal Dural Sealant

Pramand, LLC · Decision date Oct 1, 2026

MEDTECHLEDGER EXPLANATIONP220014/S013

What did the FDA approve?

FDA approved a revised protocol for the CraniSeal Registry New Enrollment Post-Approval Study (PAS) for the CraniSeal Dural Sealant from Pramand, LLC. The supplement, identified as P220014/S013, was submitted to satisfy conditions of approval in the original P220014 approval order.

The decision is limited to the PAS protocol revision; it is not a new approval of the dural sealant device itself. The source statement does not describe what specific changes were made to the protocol, nor does it provide details about the study design, endpoints, or enrollment criteria. The device is categorized as a dural sealant under product code NQR.

FDA approval order statement

Approval of the revised protocol for the CraniSeal Registry New Enrollment Post-Approval Study (PAS). The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P220014.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Neurology
Decision date
Oct 1, 2026
FDA change category
Postapproval Study Protocol

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P220014/S013
Regulatory pathway
PMA supplement
Applicant
Pramand, LLC
Product code
NQR
Decision code
APPR
Decision date
Oct 1, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Sealant, dural.

Applicant
Pramand, LLC
Product code
NQR
FDA device class
3

For the original device and its historical approval scope, see PMA P220014. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P220014 · Original PMA

    CraniSeal Dural Sealant

  2. P220014/S013 received

    Application receipt date recorded by FDA.

  3. P220014/S013 · FDA decision

    Normal 180 Day Track No User Fee

Timeline entries are records held by MedtechLedger for P220014. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P220014

Product / regulatory recordCompanyPathwayDecision dateSource
Pramand, LLCPMA approvalJul 6, 2023FDA

Explore the linked device profile

Other records with product code NQR

Product / regulatory recordCompanyPathwayDecision dateSource
Pramand, LLCPMA supplementSep 11, 2026FDA
Pramand, LLCPMA approvalFeb 14, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Pramand, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
201 Burlington Rd., Suite 210, Bedford, MA, 01730

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records